Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Juan R Rodriguez-Madoz"'
Autor:
Giulia Coppiello, Gloria Abizanda, Natalia Aguado, Elena Iglesias, Estibaliz Arellano-Viera, Juan R Rodriguez-Madoz, Xonia Carvajal-Vergara, Felipe Prosper, Xabier L. Aranguren
Publikováno v:
Stem Cell Research, Vol 21, Iss C, Pp 1-4 (2017)
We generated ATCi-MF1 induced pluripotent stem (iPS) cell line from Macaca fascicularis adult skin fibroblasts using non-integrative Sendai viruses carrying OCT3/4, KLF4, SOX2 and c-MYC. Once established, ATCi-MF1 cells present a normal karyotype, ar
Externí odkaz:
https://doaj.org/article/2ff40b6c1b0947f09bbc067b04f1c633
Autor:
Pedro Vicente, Joana I. Almeida, Inês E. Crespo, Nikolaus Virgolini, Inês A. Isidro, Maria Eréndira Calleja-Cervantes, Juan R. Rodriguez-Madoz, Felipe Prosper, Paula M. Alves, Margarida Serra
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Hepatocytes-like cells (HLC) derived from human induced pluripotent stem cells show great promise for cell-based liver therapies and disease modelling. However, their application is currently hindered by the low production yields of existing
Externí odkaz:
https://doaj.org/article/70c758a07bc245059b4c1832ecd92381
Autor:
Pedro Justicia-Lirio, María Tristán-Manzano, Noelia Maldonado-Pérez, Carmen Barbero-Jiménez, Marina Cortijo-Gutiérrez, Kristina Pavlovic, Francisco J. Molina-Estevez, Pilar Muñoz, Ana Hinckley-Boned, Juan R. Rodriguez-Madoz, Felipe Prosper, Carmen Griñán-Lison, Saúl A. Navarro-Marchal, Carla Panisello, Julia Muñoz-Ballester, Pedro A. González-Sierra, Concha Herrera, Juan A. Marchal, Francisco Martín
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 4, Pp 102308- (2024)
Although chimeric antigen receptor (CAR) T cell therapy has revolutionized type B cancer treatment, efficacy remains limited in various lymphomas and solid tumors. Reinforcing conventional CAR-T cells to release cytokines can improve their efficacy b
Externí odkaz:
https://doaj.org/article/bffb79b98bd04d24b3575e2ddc65fa95
Autor:
Sebastian Aguirre, Ana M Maestre, Sarah Pagni, Jenish R Patel, Timothy Savage, Delia Gutman, Kevin Maringer, Dabeiba Bernal-Rubio, Reed S Shabman, Viviana Simon, Juan R Rodriguez-Madoz, Lubbertus C F Mulder, Glen N Barber, Ana Fernandez-Sesma
Publikováno v:
PLoS Pathogens, Vol 8, Iss 10, p e1002934 (2012)
Dengue virus (DENV) is a pathogen with a high impact on human health. It replicates in a wide range of cells involved in the immune response. To efficiently infect humans, DENV must evade or inhibit fundamental elements of the innate immune system, n
Externí odkaz:
https://doaj.org/article/78139064b4bc4ba996ad45f43d5b6e8a
Autor:
Alessia Cavazza, Ayal Hendel, Rasmus O. Bak, Paula Rio, Marc Güell, Duško Lainšček, Virginia Arechavala-Gomeza, Ling Peng, Fatma Zehra Hapil, Joshua Harvey, Francisco G. Ortega, Coral Gonzalez-Martinez, Carsten W. Lederer, Kasper Mikkelsen, Giedrius Gasiunas, Nechama Kalter, Manuel A.F.V. Gonçalves, Julie Petersen, Alejandro Garanto, Lluis Montoliu, Marcello Maresca, Stefan E. Seemann, Jan Gorodkin, Loubna Mazini, Rosario Sanchez, Juan R. Rodriguez-Madoz, Noelia Maldonado-Pérez, Torella Laura, Michael Schmueck-Henneresse, Cristina Maccalli, Julian Grünewald, Gloria Carmona, Neli Kachamakova-Trojanowska, Annarita Miccio, Francisco Martin, Giandomenico Turchiano, Toni Cathomen, Yonglun Luo, Shengdar Q. Tsai, Karim Benabdellah
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 34, Iss , Pp 102066- (2023)
The European Cooperation in Science and Technology (COST) is an intergovernmental organization dedicated to funding and coordinating scientific and technological research in Europe, fostering collaboration among researchers and institutions across co
Externí odkaz:
https://doaj.org/article/dff3b1dde38845db9319c7538193d46c
Autor:
Cristina Calviño, Candela Ceballos, Ana Alfonso, Patricia Jauregui, Maria E. Calleja-Cervantes, Patxi San Martin-Uriz, Paula Rodriguez-Marquez, Angel Martin-Mallo, Elena Iglesias, Gloria Abizanda, Saray Rodriguez-Diaz, Rebeca Martinez-Turrillas, Jorge Illarramendi, Maria C. Viguria, Margarita Redondo, Jose Rifon, Sara Villar, Juan J. Lasarte, Susana Inoges, Ascension Lopez-Diaz de Cerio, Mikel Hernaez, Felipe Prosper, Juan R. Rodriguez-Madoz
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Despite the potential of CAR-T therapies for hematological malignancies, their efficacy in patients with relapse and refractory Acute Myeloid Leukemia has been limited. The aim of our study has been to develop and manufacture a CAR-T cell product tha
Externí odkaz:
https://doaj.org/article/f8de5ca01ff34ed9b089165eb0725060
Autor:
Enrique Conde, Noelia Casares, Uxua Mancheño, Edurne Elizalde, Enric Vercher, Roberto Capozzi, Eva Santamaria, Juan R. Rodriguez-Madoz, Felipe Prosper, Juan J. Lasarte, Teresa Lozano, Sandra Hervas-Stubbs
Publikováno v:
Molecular Therapy. 31:48-65
Regulatory T cells overwhelm conventional T cells in the tumor microenvironment (TME) thanks to a FOXP3-driven metabolic program that allows them to engage different metabolic pathways. Using a melanoma model of adoptive T cell therapy (ACT), we show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb86c315f8c335b7cc9e340499b1e61
https://doi.org/10.1016/j.ymthe.2022.08.017
https://doi.org/10.1016/j.ymthe.2022.08.017
Autor:
Rebeca Martinez-Turrillas, Angel Martin-Mallo, Saray Rodriguez-Diaz, Natalia Zapata-Linares, Paula Rodriguez-Marquez, Patxi San Martin-Uriz, Amaia Vilas-Zornoza, María E. Calleja-Cervantes, Eduardo Salido, Felipe Prosper, Juan R. Rodriguez-Madoz
Publikováno v:
Molecular Therapy - Methods & Clinical Development. 25:137-146
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::643b9a72492af84ec6fc0e3b8acf1f2f
https://doi.org/10.1016/j.omtm.2022.03.006
https://doi.org/10.1016/j.omtm.2022.03.006
Autor:
Sandra Hervas-Stubbs, Cristian Smerdou, Nathalie Thieblemont, Miguel F. Sanmamed, Maria C. Ochoa, Marta Ruiz-Guillen, Jose I. Riezu-Boj, Erkuden Casales, Uxua Mancheño, Juan R. Rodriguez-Madoz, Juan Dubrot, Mercedes Reboredo, Jose I. Quetglas, Ignacio Melero
Host responses are increasingly considered important for the efficacious response to experimental cancer therapies that employ viral vectors, but little is known about the specific nature of host responses required. In this study, we investigated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09945f2120fc5eb03c7462014beb023c
https://doi.org/10.1158/0008-5472.c.6505704
https://doi.org/10.1158/0008-5472.c.6505704
Autor:
Sandra Hervas-Stubbs, Cristian Smerdou, Nathalie Thieblemont, Miguel F. Sanmamed, Maria C. Ochoa, Marta Ruiz-Guillen, Jose I. Riezu-Boj, Erkuden Casales, Uxua Mancheño, Juan R. Rodriguez-Madoz, Juan Dubrot, Mercedes Reboredo, Jose I. Quetglas, Ignacio Melero
Supplementary Figures S1-S6. The IFN-I response innduced by SSFV-IL-12 is not affeccted by the IL-12 transgene but is impaired in the absence of IFN-I signaling (S1); IFN-I receptor function is critical for the therapeutic effect of SFV-IL-12 (S2); I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417a92cb113ef3ebaaebcf4aebb9d618
https://doi.org/10.1158/0008-5472.22400862
https://doi.org/10.1158/0008-5472.22400862